IL5 and eosinophilic granulomatosis with polyangiitis: A 30-year-old Caucasian male diagnosed with EGPA three years ago was considered for anti-IL5 treatment with benralizumab (30 mg SC every four weeks for the first eight weeks and 30mg SC every eight weeks subsequently) due to severe eosinophilic asthma with frequent exacerbations.